Disease · HP_0002902

Hyponatremia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Hyponatremia. Diseases, record HP_0002902. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002902

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Hyponatremia
Open Targets ID: HP_0002902
Other names: Decreased sodium(1+) concentration, Decreased sodium(1+) level, Decreased sodium(1+) level in blood, Low blood sodium levels, Reduced sodium(1+) concentration, Reduced sodium(1+) level, Reduced sodium(1+) level in blood
Highest stage of its drugs: Approval, for 2 of its 13 drugs, from DailyMed

Source Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOLVAPTAN	CHEMBL344159	Small molecule	Approval	DailyMed	25	24	24	Drugs and targets
SODIUM ACETATE	CHEMBL1354	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
CONIVAPTAN	CHEMBL1755	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LIXIVAPTAN	CHEMBL49429	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
SATAVAPTAN	CHEMBL2107777	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
CONIVAPTAN HYDROCHLORIDE	CHEMBL1201108	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
UREA	CHEMBL985	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ALBUMIN HUMAN	CHEMBL1201451	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AVPR2	Vasopressin V2 receptor	5	Vasopressin V2 receptor antagonist	Approval	https://conductscience.org/library/genes/554	Drugs and targets
AVPR1A	Vasopressin V1a receptor	2	Vasopressin V1a receptor antagonist	Phase 3	https://conductscience.org/library/genes/552	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 agonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 agonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
APLNR	Apelin receptor	1	Apelin receptor agonist	Unknown	https://conductscience.org/library/genes/187	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	1	Sodium/glucose cotransporter 2 inhibitor	Phase 2/3	https://conductscience.org/library/genes/6524	Drugs and targets

Trials52

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01227512	Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia	Phase 3	124	2014-10-17	Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT02449044	International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia	Phase 3	111	2016-01-21	Hyponatremia	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT01251770	Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children	Phase 3	78	2012-01-25	Hyponatremia	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01301274	0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children	Not applicable	66	2012-03-07	Hyponatremia	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00550459	Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients	Phase 3	57	2011-04-28	Hyponatremia	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT00478192	Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia	Phase 3	50	2010-04-21	Hyponatremia	CONIVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT03048747	A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH	Phase 3	16	2020-11-02	Syndrome of Inappropriate Antidiuretic Hormone Secretion	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT00843986	Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)	Phase 3	9	2010-10-01	Hyponatremia, Acute Decompensated Heart Failure	CONIVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT02012959	Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia	Phase 3	9	2018-08-28	Hyponatremia	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT01451411	A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia	Phase 3	4	2016-03-01	Hyponatremia	CONIVAPTAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials37

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tolvaptan 15-60 mg/Day vs Placebo: serious adverse events	18 of 66	9 of 55	121	NCT01227512	Trial comparisons
Hypotonic vs Isotonic: serious adverse events	4 of 34	0 of 32	66	NCT01301274	Trial comparisons
Hypotonic Arm vs Isotonic Arm: Mortality at 28 Days	3 of 32	0 of 31	63	NCT01301274	Trial comparisons
ClNa 0.3% vs ClNa 0.45%: serious adverse events	0 of 29	0 of 29	58	NCT01251770	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose	0 of 29	2 of 28	57	NCT00550459	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)	2 of 29	1 of 28	57	NCT00550459	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment	2 of 29	0 of 28	57	NCT00550459	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Pulse Rate	0 of 29	0 of 28	57	NCT00550459	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval	1 of 29	1 of 28	57	NCT00550459	Trial comparisons
Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Blood Pressure	0 of 29	2 of 28	57	NCT00550459	Trial comparisons

1 to 10 of 37

See all 37 comparisons in its trials

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20185637	RESULT	1	PubMed
16352625	RESULT	1	PubMed
15121942	RESULT	1	PubMed
12563043	RESULT	1	PubMed
42522233	DERIVED	1	PubMed
37098131	DERIVED	1	PubMed
36396331	DERIVED	1	PubMed
34693505	DERIVED	1	PubMed
30180806	DERIVED	1	PubMed
25751673	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002902

GET https://conductscience.org/api/diseases/v1/HP_0002902/trials?page=2

API reference For AI assistants